Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.51 |
| ▸ | OXTR | P30559 | 4/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.45 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | CTSG | P08311 | 2/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13113566 | 0.85 | SSTR2 (0.50) | AVPR1ACTSGKLK7ALBPLAU | |
| SCHEMBL13287941 | 0.84 | SSTR2 (0.50) | AVPR1ACTSGKLK7ALBPLAU | |
| SCHEMBL13703200 | 0.80 | MC4R (0.52) | CTSGPLAU | |
| SCHEMBL12082795 | 0.80 | IL23R (0.52) | AVPR1ACTSGPLAUTNFSF11 | |
| SCHEMBL13113585 | 0.79 | PLAU (0.51) | OXTRAVPR1AAVPR1BCTSGKLK7 | |
| SCHEMBL13287918 | 0.78 | ALB (0.47) | CTSGKLK7ALBPLAUTNFSF11 | |
| SCHEMBL13656564 | 0.78 | MC4R (0.49) | MDM2CTSGPRMT5WDR77TNFSF11 | |
| SCHEMBL13649555 | 0.78 | MC4R (0.56) | CTSGPLAU | |
| SCHEMBL13649564 | 0.78 | MC4R (0.55) | CTSGPLAU | |
| SCHEMBL13287950 | 0.78 | ALB (0.46) | CTSGKLK7ALBPLAUTNFSF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608243-B2 | RGD peptide sequence; labelled with fluorescein used as contrast agents in optical imaging in diagnosis of angiogenesis-related diseases; peptidic vector and the fluorescein dye are coupled; cyclic peptide forming disulife or monothioether bridge | GE HEALTHCARE AS (NO) | 2009-10-27 | — | — | US | disclosed |
| US-20090232741-A1 | Optical Imaging | GE HEALTHCARE AS (NO) | 2009-09-17 | — | — | US | disclosed |
| US-20070183977-A1 | Fluorescein-labelled peptides | AMERSHAM HEALTH AS (NO) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070183977-A1 | Fluorescein-labelled peptides | FLT4, FLT1, KDR | MDM2 2912/4885OXTR 1139/4885AVPR1A 388/4885 |
| US-20090232741-A1 | Optical Imaging | AGER, KDR, FLT4 | MDM2 4012/4885OXTR 47/4885AVPR1A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.